Article

May 16, 2012

Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy

Dr. Singh discusses CVS Caremark's strategies for managing oncology spending.

Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, states that there are a variety of approaches used to stem the rise of costs associated with oncology. However, Dr. Singh point out that there is not a one-size-fits-all approach to doing so.

Related Videos

Don M. Benson, MD, PhD, James Cancer Hospital

Edgardo S. Santos, MD, FACP, FASCO

Firas El Chaer, MD, smiling during a video interview

Firas El Chaer, MD, smiling during a video interview

Mikael Eriksson, PhD.

Roberto Salgado, MD.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine

Screenshot of an interview with Shaun P. McKenzie, MD

Hans Lee, MD

Don M. Benson, MD, PhD, James Cancer Hospital

Related Content

FDA approved. | Image Credit: Pawel - stock.adobe.com .jpeg

January 2nd 2025

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

December 26th 2024

Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.

gastric cancer | Image credit: Crystal light - stock.adobe.com

January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com

January 1st 2025

Overcoming Barriers to Guideline-Directed Cardiometabolic Care

Hayden E. Klein

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance initiatives are key to addressing therapeutic inertia.

Jennifer Vaughn, MD, smiling during a zoom interview

January 1st 2025

Personalizing MPN Disease Management and Monitoring

Laura Joszt, MA

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and managed in the long term, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.

Related Content

FDA approved. | Image Credit: Pawel - stock.adobe.com .jpeg

January 2nd 2025

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

December 26th 2024

Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.

gastric cancer | Image credit: Crystal light - stock.adobe.com

January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com

January 1st 2025

Overcoming Barriers to Guideline-Directed Cardiometabolic Care

Hayden E. Klein

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance initiatives are key to addressing therapeutic inertia.

Jennifer Vaughn, MD, smiling during a zoom interview

January 1st 2025

Personalizing MPN Disease Management and Monitoring

Laura Joszt, MA

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and managed in the long term, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions